US2853420A - Ethyl cellulose coatings for shaped medicinal preparations - Google Patents

Ethyl cellulose coatings for shaped medicinal preparations Download PDF

Info

Publication number
US2853420A
US2853420A US598841A US59884156A US2853420A US 2853420 A US2853420 A US 2853420A US 598841 A US598841 A US 598841A US 59884156 A US59884156 A US 59884156A US 2853420 A US2853420 A US 2853420A
Authority
US
United States
Prior art keywords
coatings
coating
granules
action
delaying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US598841A
Inventor
Lowey Hans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US598841A priority Critical patent/US2853420A/en
Application granted granted Critical
Publication of US2853420A publication Critical patent/US2853420A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005Coating of tablets or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Definitions

  • This invention relates to shaped medical preparations and especially to the coating of medicating carriers.
  • One of the objects of the invention is to provide on granulated carriers of predetermined shape, one or more action affecting multi-coat layers of predetermined structure and dimensions, and of high elasticity so as substantially not to be affected in their action by the further handling of the. granules and especially during shaping or compression of several granules into capsules or tablets of predetermined shape, structure and dimensions.
  • a preferred object of the invention is to provide so many coatings or a layer of such thickness while maintaining a predetermined solidity and elasticity as to permit complete postponement or exclusion of action for such a great period, i. e., several hours, as to insure any action to occur only after a predetermined delay, for example, after passage through the stomach.
  • Such relatively thick layers are in contrast to relatively thin layers which merely cause medication to start slowly but immediately, with the result of a more sustained action instead of a delayed action.
  • Another object of the invention is to provide a multicoat layer on a granulated medication containing carrier having so many coatings as to insure the occurrence of a predetermined action delaying or action sustaining effect, within certain permissible tolerances, even in case some of vthese coatings would be inhomogenous or imperfect due to inaccuracies which may be incidental or accidental to existing production methods or facilities.
  • Still another object of the invention is to provide multicoat layers each including a large plurality of successive coatings, and wherein each plurality of coatings gradually decreases in thickness from the bottom to the top layer of such plurality, while the bottom layer of each plurality of coatings may be caused to increase in thickness, in a manner preferably proportional to its radius or to the distance of the coating from the center of the granule.
  • a further object of the invention is to insure or enhance elasticity and occurrence of the desired action delay after consumption of a finished tablet or capsule by applying the multi-coat layer or layers to a medically active, round granulated carrier, and reducing the thickness of each individual coating to a thickness which is not more than one percent of its radius or a fraction thereof, preferably for a granule of a diameter of .05", the thickness of each individual coating should be reduced to the order of magnitude of .0OO25.
  • an object of the invention is to provide on granulated round carriers multi-coat layers of a pH- wise substantially neutral structure, so as to reduce to a minimum the effect of the usually varying individual acid or alkaline conditions prevailing in the part or parts of the human body receiving the tablet or capsule, whether such tablet or capsule is to be effective in the stomach or in the intestines or in both, thereby maying the effect of the stomach or intestinal juices, whether alkaline or acid, more closely proportional to the number of coatings and thus more accurately predeterminable than it would be with the use of pH-wise non-neutral, or acid or alkaline coatings.
  • imperfections in such substantially neutral coatings such as varying thickness or even ruptures or fissures will have less effect upon the desired action delay, in contrast to imperfections in acid or alkaline coatings which once broken at one point would permit either the acid stomach uid or the alkaline intestinal fluid, as the case may be, to break through rather quickly to the granulated medically active core, thus causing it to act prematurely thereby destroying any intended predetermined actional sustaining or action delaying effect of these coatings.
  • the individual coatings in a multi-coat'layer are substantially separated from each other or from any preceding or ⁇ succeeding coating.
  • a preferred object of the invention is to separate the individual coatings by a thin layer of extremely nely ground filler particles such as talcum, which serve to maintain an effective separation of adjacent coatings even though the bottom coating may not be completely dry when a succeeding coating is applied. In fact such complete dryness is not desired firstly because it would unduly extend time of manufacture, and, secondly, the succeeding coating would have difficulty adhering to a completely dried out bottom surface.
  • the powder layer applied to a not-completely-dried-out and therefore still somewhat soft bottom layer will cause a roughening of its surface, which while holding the two adjacent coatings substantially separate and apart from each other, will cause a succeeding coating safely to adhere to its bottom coating while at the same time imparting to its top coating a structure substantially independent from that of the bottom coating.
  • openings in one coating will not necessarily communicate with openings in the other coating, and therefore the probability of a break-through, through a number of coatings of the juices affecting the multicoated granule is reduced, or rather limited to single coatings only.
  • Still another object of the invention is to provide multicoat action sustaining or action delaying layers on nongranulated carriers and even medical substances in powder and even tablet form such as aspirin powder or tablets.
  • Still further another object of the invention is to provide action sustaining or action delaying coatings on immediate action substances other than those of a medical nature such as biologically active substances or carrier of such substances, such as fertilizers, herbicides or insecticides in powder or tablet form.
  • Fig. l represents cross section through a granulated carrier embodying certain principles of the invention and Fig. 2 a combination of granules differentially coated also in accordance with the invention.
  • a granulated carrier of round shape such as produced in the usual manner in a rotating pan from sugar or corn starch is schematically indicated at 1. It may either contain or be impregnated with a medicating substance such as nitroglycerin.
  • granule 1 is provided in accordance with the invention, first, with amedicating impregnation 2 containing, for example, a medically active substance such as nitroglycerin compound in an amount of say 50% of the weight of the granule 1.
  • amedicating impregnation 2 containing, for example, a medically active substance such as nitroglycerin compound in an amount of say 50% of the weight of the granule 1.
  • Impregnation 2 is applied in one impregnation step or preferably in several steps of a number which may be somewhat less than the number of coating steps involved in the application of action sustaining or action delaying coatings.
  • medicating impregnation or coating 2 has been applied in twelve successive steps each involving a medicating layer of substantially not larger dimensions than the subsequent action sustaining or action delaying layers, with the difference that the resulting medicating layer 2 forms, at least partially, not only a coating but also an impregnation for the granule 1.
  • the penetration of the medically active coating into the interior of granule 1 causes a dimunition in the thickness which for that reason and depending upon the internal structure of granule 1, may be thinner than the corresponding action sustaining or action delaying coatings, all this without departing from the scope of this invention.
  • the diameter of the granules has been found to be of the order of .05" and a thickness of each coating applied thereon of the order of M000 of a percent of its radius or 000025".
  • the number of coatings forming one action sustaining or delaying layer and which are indicated in Fig. l from 3 to 6 consists of the order of 25 and similarly each successive layer has been established as of the order of 25 coatings.
  • Such 25 coatings of the dimensions indicated above have been found to provide a sustained action effect of the duration of approximately one hour, provided the granules contain a medicating substance or coating or are to be medically active; or, as the case may be, an action delaying effect of two hours provided there are 50 coatings applied in succession.
  • the object of this procedure was to obtain a nitroglycerin containing tablet releasing the nitroglycerin gradually and practically proportionally during a period of approximately ten hours and in such a manner as not to become destroyed when released in the patients stomach and not produce any shock effect upon the patient when released in his intestinal tract.
  • a predetermined amount of say 100 pounds of granulated material is worked in a rotating pan in otherwise well known manner, into substantially round granules which, after sieving and, if necessary, regranulating of the residues, are transformed into 200 pounds of granules of substantially equal size, for example, of between ten to twenty mesh or a diameter of approximately .05 each.
  • the 200 pounds of .05" diameter granules are rst coated with a lesser number of say, l2 medicating coatings increasing the weight of the granules from 200 to 201.5 lbs. and thereafter with one or several multiple coatings each consisting of 25 separate coatings, whereby each of these coatings is produced by one pound of a coating solution containing a very high percentage of solvent, weighing at least several times as much as the coating material itself.
  • the solution is an 85% alcohol solutio-n containing 15% of a cellulose compound containing at least one of the following substances: methyl cellulose, ethyl cellulose, and cellulose acetate, phthalate or derivatives thereof; this solution also includes a few percentages (of the order of about 10%) of beeswax and castor oil which add to increase plasticity and elasticity of the coatings, respectively.
  • the alcohol solvent may be replaced by chloroform, if necessary; all this without exceeding the scope of the invention, although ethyl cellulose has been found as contributing a maximum of elasticity to the final coatings and a minimum of inaccuracies and imperfections.
  • the coating solution be substantially neutral or of the order of 7 pH.
  • the coating itself is effected in a rotating pan of usual construction of a diameter of around 38 inches but r0- tating with a speed of 50 to 60 R. P. M. in contrast to the usual 30 R. P. M.
  • the coating operation itself and the rotation of the pan occurs for a duration of around five minutes until the entire one pound solution is transformed into coatings; then a drying operation of around 10 minutes or twice as much as the coating tim-e is applied. Thereafter a separating layer is applied to the dry yet still soft coating in the form of very ne talcum powder estimated to be of not more than the order of coating thickness, or between about 1000 and 10,000 mesh.
  • the drying is preferably effected in a flow of warm air of slightly above room temperature, preferably at around Fahrenheit.
  • the first action sustaining or delaying coating is applied in the form of a one pound alcohol solution as mentioned above and immediately after drying after talcum dusting
  • the second coating 4 is applied in the form of a 1 lb. solution substantially identical with the previous solution whereafter another dusting procedure takes place. This process is continued until 25 coatings have been applied, always using a l lb. alcohol solution of cellulose compound.
  • the result will be 187.05 pounds of granules each granule containing 50 coatings of predetermined thickness and providing an action sustaining period of two hours.
  • this tablet or capsule By combining one or preferably several granules, in the abovementioned example granules, of each batch, into a tablet or capsule, this tablet or capsule will provide an action sustaining or delaying effect gradually extending over ten hours.
  • granule 17 is shown carrying a 12-coat impregnation 18 and a Z50-coat action delaying layer 19.
  • Granules 20 and 21 are shown to have in addition to and on top of the 12-coat medically active impregnation 22, a coat action delaying layer 23, while granule 24 carries in addition to medicating impregnation 25, a 50-coat action delaying layer 26, and granules 27, 28 carrying in addition to medicating layers 29, a 1GO-coat action delaying layer 30.
  • any desired number of granules having any desired number of coatings in accordance with the invention and in addil tion to medically active granules such as shown at 17, 20, 21, 27 and 28, a number of medically inactive liller granules preferably of irregular shape such as shown in Fig. 2, at 31, 32, which protect the medically active granules from breakage or any other action distorting effects.
  • a time delaying action is intended, i. e., an action in which for a predetermined time, for example, during the passage of the tablet through the stomach, no medicating effect at all is produced, while thereafter, namely, in the intestines, a medicating cricet, for example, a sustained action medicating effect is to be realized.
  • two hundred pounds of granules or powder particles of any shape not necessarily round but preferably of the general diametrical dimensions mentioned above are coated in a first operational step with fty separate coatings preferably of the dimensions mentioned above, each involving an intermediate dusting and a one pound coating solution similar to that mentioned above in its first step.
  • the rst 50 coatings cause a delay time of approximately two hours, i. e., for a duration sutlcient to permit a tablet or capsule containing such granules or powder particles to be passed through the acid stomach and to the alkaline intestines, provided, of course, that in accordance with the invention the coatings are of a pH-wise substantially neutral structure.
  • the result of such coating procedure will be an amount of 206 pounds of granules, or particles, each providing a two hour delayed action period. Thereafter one fourth of this batch is removed from the pan and the balance is subjected to a second coating step whereas an amount of coating solution proportional to the remaining weight of the granules or particles is added, and 50 successive coating operations are applied in a manner similar to that of the rst operation.
  • two further batches of a size substantially equal to the first removed batch are removed from the coating pan.
  • the nal product of these four coating operations each containing 50 coating steps will be a mixture of four batches of granules or particles containing equal amounts of two, four, six and eight hour action delaying coatings.
  • a tablet or capsule made with a mixture of such granules or particles will produce no action whatever in the stomach but will produce action delaying effects for a period of approximately eight hours in the intestinal tract.
  • the different batches of granules are produced in simultaneous coating steps instead of in successive coating steps as before.
  • a rst batch of 50 pounds of granules or particles of a general size such as mentioned above is provided in a rotating pan with fifty coatings of dimensions such as mentioned above and in the manner stated above and with the use of a coating solution such as exemplified in one of the previous examples.
  • the result will be lbs. of granules or particles, 50 lbs. thereof providing an action delay of two hours and another 50 lbs. thereof providing an action delay of four hours.
  • a third 50 lb. batch of granules or particles is added and the three batches are coated in the pan in substantially the same manner as stated above with fifty appropriate coatings, dimensioned in accordance with the invention.
  • a fourth 50 lb. batch of granules or particles is added and the pan is rotated and fty further coatings are applied to these four batches in accordance with the invention.
  • the result of these four process steps will be a 200 1b. mixture of granules or particles, containing in equal proportions action delaying coatings for two, four, six and eight hours respectively.
  • This mode of procedure has the advantage that the last or top layer of multiple coatings which are applied to all four batches and to every one of the 200 lbs. of granules or particles, can be made of any desired thickness corresponding to any amount of predetermined action delaying time such as several hours, while the underlying coatings may be relatively thinner corresponding 7 only to action sustention periods such as durations of one hour only or multiples thereof.
  • a fourth mode of coating procedure four separate 50 lb. batches of appropriately shaped granules or particles are processed completely separately. Each of these batches is treated separately, the rst batch with 50 coatings, the second batch with 100 coatings, the third batch with 150 coatings and the fourth batch with 200 coatings, all applied in accordance with the invention.
  • a tablet or capsule made of a mixture of equal quantities of these four granules or particles and derived from each of these four batches will have no eiect whatever for two hours and therefore it will be able to pass the stomach substantially unaffected; it will only be effective after two hours, i. e., in the intestinal tract, and in this location it will be gradually effective for a duration of altogether eight hours one granule being effective over each pair of successive hours.
  • the invention is not limited to the exact coating procedures, amounts and structures shown and described but may be applied in any proportion and sequence whatsoever. It is especially possible in accordance with the invention to obtain wide variations and mixtures for action delay and action sustention in a predetermined manner, to increase one or the other of these effects.
  • a number of substantially round medically inactive granulated carriers each having an impregnation of a solution of therapeutically active material in ethylcellulose and upon said impregnation a number of action-delaying ethylcellulose coatings, the number of coatings on at least some of said carriers being different from the number on the remaining carriers by at least said 25 coatings containing a total amount of coating material of the order of 1% of the weight of the inactive carrier substantially equally divided among said 25 coatings, and each of said coatings being substantially not thicker than .1% of its radius.
  • said medically active impregnation contains nitroglycerin and said total amount of ethylcellulose coating material is approximately 1.5 ofthe weight of the medically inactive carrier, and wherein each of said coatings has a thickness of the order of .000025 inch; said carriers having a granule diameter of .05 inch; the diameter of the largest medically active coated carrier being approximately greater than the diameter of the smallest medically active coated carrier.
  • each of said medically impregnated ethylcellulose coated carriers is additionally provided with at least 25 ethylcellulose top coatings containing a total amount of coating material of the order of 1.5 of the weight of the medically inactive carrier; said amount being divided substantially equally among said 25 top coatings, and each of said top coatings being substantially not thicker than .1% of its radius.
  • a coating process the steps of coating medically inactive granules in a rotating pan to a substantially round shape, sieving the granules to a substantially equal size, impregnating said granules with a medicating substance in an ethylcellulose solution and coating thereon an action delaying ethylcellulose layer in the form of at least 25 substantially separate successive coating steps; the 25 coatings containing a total amount of coating material of the order of 1% of the weight of the medically inactive granule substantially equally divided among said 25 coatings; each coating being followed by an intermediate drying step and each action delaying coating having a thickness of the order of 1/10% of the radius of the medically inactive granule.
  • said medically active impregnation contains nitroglycerin and said total amount of ethylcellulose coating material is approximate- Lio ly 1.5 of the weight of the medically inactive granule and, wherein said granules are of the order of .05 inch diameter, each coating being ofthe order of .000025 inch; and wherein there are a further number of medically impregnated granules coated in said pan and provided with so many successive ethylcellulose coatings as to increase the diameter of the coated granules to approximately 30% of the diameter of the medically impregnated granules containing only 25 ethylcellulose coatings; the thickness of all the coatings on different granules being a multiple of the thickness of all the coatings on said granules containing only 25 ethylcellulose coatings.
  • each of said medically impregnated ethylcellulose granules ⁇ is additionally provided with at least 25 ethylcellulose top coatings containing a total amount of coating material of the order of 1.5% of the weight of the medically inactive granules; said amount being divided substantially equally among said 25 top coatings, and each of said top coatings being substantially not thicker than .1% of its radius.
  • Clarkson Tablet Coating, 1951, Drug and Cos. Ind., N. Y., pp. 59-.65.

Description

Sept. 23, 1958 H. LOWEY 2,853,420
ETHYI.. CELLULOSE COATINGS FOR SHAPED MEDICINAL PREPARATIONS Filed July 19, 1956 TAL-CUM DUST l T ANA! LESS H TORG ATTDRNEY United States Patent O ETHYL CELLULOSE COATINGS FOR SHAPED MEDICINAL PREPARATIONS Hans Lowey, Larchmont, N. Y.
Application July 19, 1956, Serial No. 598,841
8 Claims. (Cl. 167-82) This invention relates to shaped medical preparations and especially to the coating of medicating carriers.
One of the objects of the invention is to provide on granulated carriers of predetermined shape, one or more action affecting multi-coat layers of predetermined structure and dimensions, and of high elasticity so as substantially not to be affected in their action by the further handling of the. granules and especially during shaping or compression of several granules into capsules or tablets of predetermined shape, structure and dimensions.
A preferred object of the invention is to provide so many coatings or a layer of such thickness while maintaining a predetermined solidity and elasticity as to permit complete postponement or exclusion of action for such a great period, i. e., several hours, as to insure any action to occur only after a predetermined delay, for example, after passage through the stomach. Such relatively thick layers are in contrast to relatively thin layers which merely cause medication to start slowly but immediately, with the result of a more sustained action instead of a delayed action.
Another object of the invention is to provide a multicoat layer on a granulated medication containing carrier having so many coatings as to insure the occurrence of a predetermined action delaying or action sustaining effect, within certain permissible tolerances, even in case some of vthese coatings would be inhomogenous or imperfect due to inaccuracies which may be incidental or accidental to existing production methods or facilities.
Still another object of the invention is to provide multicoat layers each including a large plurality of successive coatings, and wherein each plurality of coatings gradually decreases in thickness from the bottom to the top layer of such plurality, while the bottom layer of each plurality of coatings may be caused to increase in thickness, in a manner preferably proportional to its radius or to the distance of the coating from the center of the granule.
A further object of the invention is to insure or enhance elasticity and occurrence of the desired action delay after consumption of a finished tablet or capsule by applying the multi-coat layer or layers to a medically active, round granulated carrier, and reducing the thickness of each individual coating to a thickness which is not more than one percent of its radius or a fraction thereof, preferably for a granule of a diameter of .05", the thickness of each individual coating should be reduced to the order of magnitude of .0OO25.
Still further an object of the invention is to provide on granulated round carriers multi-coat layers of a pH- wise substantially neutral structure, so as to reduce to a minimum the effect of the usually varying individual acid or alkaline conditions prevailing in the part or parts of the human body receiving the tablet or capsule, whether such tablet or capsule is to be effective in the stomach or in the intestines or in both, thereby maying the effect of the stomach or intestinal juices, whether alkaline or acid, more closely proportional to the number of coatings and thus more accurately predeterminable than it would be with the use of pH-wise non-neutral, or acid or alkaline coatings.
ice
At the same time as a further object of the invention, imperfections in such substantially neutral coatings such as varying thickness or even ruptures or fissures will have less effect upon the desired action delay, in contrast to imperfections in acid or alkaline coatings which once broken at one point would permit either the acid stomach uid or the alkaline intestinal fluid, as the case may be, to break through rather quickly to the granulated medically active core, thus causing it to act prematurely thereby destroying any intended predetermined actional sustaining or action delaying effect of these coatings.
As a more specific object of the invention, therefore, the individual coatings in a multi-coat'layer are substantially separated from each other or from any preceding or `succeeding coating.
A preferred object of the invention, is to separate the individual coatings by a thin layer of extremely nely ground filler particles such as talcum, which serve to maintain an effective separation of adjacent coatings even though the bottom coating may not be completely dry when a succeeding coating is applied. In fact such complete dryness is not desired firstly because it would unduly extend time of manufacture, and, secondly, the succeeding coating would have difficulty adhering to a completely dried out bottom surface.
On the other hand, the direct application of a succeeding coating on a wet or humid bottom coating would tend to make the two adjacent coatings structurally one, causing one coating to share its defects with the other one in more or less the same manner and location, and thereby destroying or impairing the safety in effect, achieved by separating a great number of thin coatings in accordance withvthe invention.
In accordance with another feature of the invention, the powder layer applied to a not-completely-dried-out and therefore still somewhat soft bottom layer will cause a roughening of its surface, which while holding the two adjacent coatings substantially separate and apart from each other, will cause a succeeding coating safely to adhere to its bottom coating while at the same time imparting to its top coating a structure substantially independent from that of the bottom coating. Thus, for example, openings in one coating will not necessarily communicate with openings in the other coating, and therefore the probability of a break-through, through a number of coatings of the juices affecting the multicoated granule is reduced, or rather limited to single coatings only.
Still another object of the invention is to provide multicoat action sustaining or action delaying layers on nongranulated carriers and even medical substances in powder and even tablet form such as aspirin powder or tablets.
Still further another object of the invention is to provide action sustaining or action delaying coatings on immediate action substances other than those of a medical nature such as biologically active substances or carrier of such substances, such as fertilizers, herbicides or insecticides in powder or tablet form.
All these features of the invention, especially those resulting from the specific coating structures and procedures applied in this disclosure permit wide and predetermined variations in the effectiveness of medical preparations such as tablets and capsules.
These and other objects of theinvention will be more fully disclosed in the drawings annexed herewith in which Fig. l represents cross section through a granulated carrier embodying certain principles of the invention and Fig. 2 a combination of granules differentially coated also in accordance with the invention.
According to Fig. l a granulated carrier of round shape such as produced in the usual manner in a rotating pan from sugar or corn starch is schematically indicated at 1. It may either contain or be impregnated with a medicating substance such as nitroglycerin.
In the latter case, granule 1 is provided in accordance with the invention, first, with amedicating impregnation 2 containing, for example, a medically active substance such as nitroglycerin compound in an amount of say 50% of the weight of the granule 1.
Impregnation 2 is applied in one impregnation step or preferably in several steps of a number which may be somewhat less than the number of coating steps involved in the application of action sustaining or action delaying coatings.
In the present case medicating impregnation or coating 2 has been applied in twelve successive steps each involving a medicating layer of substantially not larger dimensions than the subsequent action sustaining or action delaying layers, with the difference that the resulting medicating layer 2 forms, at least partially, not only a coating but also an impregnation for the granule 1.
Since preferably substantially the same coating is used to apply the medicating substance as in the application of the subsequent action sustaining or action delaying coatings, the penetration of the medically active coating into the interior of granule 1 causes a dimunition in the thickness which for that reason and depending upon the internal structure of granule 1, may be thinner than the corresponding action sustaining or action delaying coatings, all this without departing from the scope of this invention.
Upon medicating impregnation or impregnations 2, a great number of extremely thin action sustaining or action delaying coatings are applied schematicaly indicated as an example at 3, 4, 5 and 6 of Fig. l without, however, being limited to such number. Each of these coatings should have a dimension not exceeding a few percent of the radius of the granule and generally each coating should have a thickness not exceeding a few percent of its radius.
It has also been found from experiments underlying the invention that a great number, preferably at least ten coatings must be applied in order to give the resulting multi-coat layer a predetermined action sustaining effect, and at least twenty coatings must be applied to obtain a predetermined time delaying eiect.
In a preferred embodiment of the invention, the diameter of the granules has been found to be of the order of .05" and a thickness of each coating applied thereon of the order of M000 of a percent of its radius or 000025".
In a preferred embodiment of the invention further the number of coatings forming one action sustaining or delaying layer and which are indicated in Fig. l from 3 to 6 consists of the order of 25 and similarly each successive layer has been established as of the order of 25 coatings. Such 25 coatings of the dimensions indicated above have been found to provide a sustained action effect of the duration of approximately one hour, provided the granules contain a medicating substance or coating or are to be medically active; or, as the case may be, an action delaying effect of two hours provided there are 50 coatings applied in succession.
In a particular example, it has been found that on a granule of a diameter of .05" the application of 250 coatings of an average thickness of 000025 will increase the diameter of each granule by about 30% from .05" to .065. By manufacturing in this manner ten types or batches of granules containing ten different multi-coat layers of different multiples of 25 coatings, each of these multi-coat layers will provide an action sustaining eiect for a predetermined multiple of hours. In this way a substantially continuous action sustaining effect is obtained, which, in accordance with this invention can be made to extend altogether over 10 hours with a considerable degree of accuracy and within economically reasonable production tolerances.
In order to produce such action sustaining or action delaying effects of relatively long duration, in one example of the invention, the following procedure is applied:
The object of this procedure was to obtain a nitroglycerin containing tablet releasing the nitroglycerin gradually and practically proportionally during a period of approximately ten hours and in such a manner as not to become destroyed when released in the patients stomach and not produce any shock effect upon the patient when released in his intestinal tract.
In order to achieve such a gradual release in a first step of procedure, a predetermined amount of say 100 pounds of granulated material is worked in a rotating pan in otherwise well known manner, into substantially round granules which, after sieving and, if necessary, regranulating of the residues, are transformed into 200 pounds of granules of substantially equal size, for example, of between ten to twenty mesh or a diameter of approximately .05 each.
These 200 lbs. of granules are now subjected to a great number of coating operations in a rotating pan, in otherwise well known manner, except that in accordance with the invention the coating solution applied is of a substantially lower concentration than usual and the speed of the rotating pan is of a substantially higher order than the usual.
Both these features cooperate to produce an extremely thin coating of extremely high elasticity and solidity, especially when superimposed in large numbers.
In a particular example of such coating operation the 200 pounds of .05" diameter granules are rst coated with a lesser number of say, l2 medicating coatings increasing the weight of the granules from 200 to 201.5 lbs. and thereafter with one or several multiple coatings each consisting of 25 separate coatings, whereby each of these coatings is produced by one pound of a coating solution containing a very high percentage of solvent, weighing at least several times as much as the coating material itself. In a particular example the solution is an 85% alcohol solutio-n containing 15% of a cellulose compound containing at least one of the following substances: methyl cellulose, ethyl cellulose, and cellulose acetate, phthalate or derivatives thereof; this solution also includes a few percentages (of the order of about 10%) of beeswax and castor oil which add to increase plasticity and elasticity of the coatings, respectively.
The alcohol solvent may be replaced by chloroform, if necessary; all this without exceeding the scope of the invention, although ethyl cellulose has been found as contributing a maximum of elasticity to the final coatings and a minimum of inaccuracies and imperfections.
It has also been found of importance for the effects characteristic of the invention that the coating solution be substantially neutral or of the order of 7 pH.
It should be noted that in order to obtain exactly predetermined coatings the solvent must be applied irnmediately before coating.
The coating itself is effected in a rotating pan of usual construction of a diameter of around 38 inches but r0- tating with a speed of 50 to 60 R. P. M. in contrast to the usual 30 R. P. M.
The coating operation itself and the rotation of the pan occurs for a duration of around five minutes until the entire one pound solution is transformed into coatings; then a drying operation of around 10 minutes or twice as much as the coating tim-e is applied. Thereafter a separating layer is applied to the dry yet still soft coating in the form of very ne talcum powder estimated to be of not more than the order of coating thickness, or between about 1000 and 10,000 mesh.
The drying is preferably effected in a flow of warm air of slightly above room temperature, preferably at around Fahrenheit.
Thus in accordance with the invention, upon the medicating impregnation or impregnations 2 the first action sustaining or delaying coating is applied in the form of a one pound alcohol solution as mentioned above and immediately after drying after talcum dusting, the second coating 4 is applied in the form of a 1 lb. solution substantially identical with the previous solution whereafter another dusting procedure takes place. This process is continued until 25 coatings have been applied, always using a l lb. alcohol solution of cellulose compound.
Thus this irst action sustaining or delaying coating procedure will increase the weight of the granules from 201.5 to 204.5 pounds.
Thereafter one-tenth of the granules corresponding to an action sustaining period of one hour, namely, 20.45 lbs. are removed and stored separately and the balance Vof the granules, i. e. 184.05 lbs. is subjected to another coatingprocedure again involving 25 separate coating operations, each using again a 1 lb. 85% cellulose compound coating solutions, resulting in coatings 12, 13, 14 etc. with intermediate talcum dust layers 15, 16, etc.
The result will be 187.05 pounds of granules each granule containing 50 coatings of predetermined thickness and providing an action sustaining period of two hours.
In a third operation, now, one-ninth of this amount, namely 20.75 pounds of granules, is removed and put aside; the balance, namely an amount of 166.30 pounds of granules, is subjected to 25 successive coating operations each involving a 1 lb. 85% cellulose compound solution. As a result of this third operational step 169.3 pounds of granules are obtained containing granules having each a three hour action sustaining effect.
This coating procedure is now continued until, nally, ten batches of granules are obtained, representing ten different multiples of 25 coatings corresponding to ten different action sustaining periods, extending from one to ten hours, respectively.
By combining one or preferably several granules, in the abovementioned example granules, of each batch, into a tablet or capsule, this tablet or capsule will provide an action sustaining or delaying effect gradually extending over ten hours.
Part of such a tablet in cross section is shown in Fig. 2 where granule 17 is shown carrying a 12-coat impregnation 18 and a Z50-coat action delaying layer 19. Granules 20 and 21 are shown to have in addition to and on top of the 12-coat medically active impregnation 22, a coat action delaying layer 23, while granule 24 carries in addition to medicating impregnation 25, a 50-coat action delaying layer 26, and granules 27, 28 carrying in addition to medicating layers 29, a 1GO-coat action de laying layer 30.
There may be combined, of course, in a tablet, any desired number of granules having any desired number of coatings in accordance with the invention and in addil tion to medically active granules such as shown at 17, 20, 21, 27 and 28, a number of medically inactive liller granules preferably of irregular shape such as shown in Fig. 2, at 31, 32, which protect the medically active granules from breakage or any other action distorting effects.
In another example of the invention only four such batch steps are involved. In this case, in a first step, a time delaying action is intended, i. e., an action in which for a predetermined time, for example, during the passage of the tablet through the stomach, no medicating effect at all is produced, while thereafter, namely, in the intestines, a medicating cricet, for example, a sustained action medicating effect is to be realized.
In this particular case and in this particular example two hundred pounds of granules or powder particles of any shape not necessarily round but preferably of the general diametrical dimensions mentioned above, are coated in a first operational step with fty separate coatings preferably of the dimensions mentioned above, each involving an intermediate dusting and a one pound coating solution similar to that mentioned above in its first step. In this way the rst 50 coatings cause a delay time of approximately two hours, i. e., for a duration sutlcient to permit a tablet or capsule containing such granules or powder particles to be passed through the acid stomach and to the alkaline intestines, provided, of course, that in accordance with the invention the coatings are of a pH-wise substantially neutral structure.
The result of such coating procedure will be an amount of 206 pounds of granules, or particles, each providing a two hour delayed action period. Thereafter one fourth of this batch is removed from the pan and the balance is subjected to a second coating step whereas an amount of coating solution proportional to the remaining weight of the granules or particles is added, and 50 successive coating operations are applied in a manner similar to that of the rst operation.
After two further and successive coating steps, two further batches of a size substantially equal to the first removed batch are removed from the coating pan.
As a result of these four coating steps each including fifty individual coating operations, four batches of granules or particles are obtained each batch corresponding to two, four, six and eight hours of action delaying periods.
The nal product of these four coating operations each containing 50 coating steps will be a mixture of four batches of granules or particles containing equal amounts of two, four, six and eight hour action delaying coatings.
In other words a tablet or capsule made with a mixture of such granules or particles will produce no action whatever in the stomach but will produce action delaying effects for a period of approximately eight hours in the intestinal tract.
In order to achieve a more pronounced or prolonged preliminary action delaying effect, in another example of the invention the different batches of granules are produced in simultaneous coating steps instead of in successive coating steps as before.
In order to explain this matter still further an example of this type of procedure will be given.
A rst batch of 50 pounds of granules or particles of a general size such as mentioned above is provided in a rotating pan with fifty coatings of dimensions such as mentioned above and in the manner stated above and with the use of a coating solution such as exemplified in one of the previous examples.
Thereafter in another successive coating operation a second 50 lb. batch of equal character is added to the rst batch and fifty further coatings are applied to both batches with corresponding amounts of solution in accordance with the invention.A
The result will be lbs. of granules or particles, 50 lbs. thereof providing an action delay of two hours and another 50 lbs. thereof providing an action delay of four hours.
Now, in a third step of this procedure, a third 50 lb. batch of granules or particles is added and the three batches are coated in the pan in substantially the same manner as stated above with fifty appropriate coatings, dimensioned in accordance with the invention.
Thereafter, in a fourth coating step, a fourth 50 lb. batch of granules or particles is added and the pan is rotated and fty further coatings are applied to these four batches in accordance with the invention. The result of these four process steps will be a 200 1b. mixture of granules or particles, containing in equal proportions action delaying coatings for two, four, six and eight hours respectively.
This mode of procedure has the advantage that the last or top layer of multiple coatings which are applied to all four batches and to every one of the 200 lbs. of granules or particles, can be made of any desired thickness corresponding to any amount of predetermined action delaying time such as several hours, while the underlying coatings may be relatively thinner corresponding 7 only to action sustention periods such as durations of one hour only or multiples thereof.
In a fourth mode of coating procedure, four separate 50 lb. batches of appropriately shaped granules or particles are processed completely separately. Each of these batches is treated separately, the rst batch with 50 coatings, the second batch with 100 coatings, the third batch with 150 coatings and the fourth batch with 200 coatings, all applied in accordance with the invention. A tablet or capsule made of a mixture of equal quantities of these four granules or particles and derived from each of these four batches will have no eiect whatever for two hours and therefore it will be able to pass the stomach substantially unaffected; it will only be effective after two hours, i. e., in the intestinal tract, and in this location it will be gradually effective for a duration of altogether eight hours one granule being effective over each pair of successive hours.
The invention is not limited to the exact coating procedures, amounts and structures shown and described but may be applied in any proportion and sequence whatsoever. It is especially possible in accordance with the invention to obtain wide variations and mixtures for action delay and action sustention in a predetermined manner, to increase one or the other of these effects.
I claim:
l. In a medically active shaped preparation, a number of substantially round medically inactive granulated carriers, each having an impregnation of a solution of therapeutically active material in ethylcellulose and upon said impregnation a number of action-delaying ethylcellulose coatings, the number of coatings on at least some of said carriers being different from the number on the remaining carriers by at least said 25 coatings containing a total amount of coating material of the order of 1% of the weight of the inactive carrier substantially equally divided among said 25 coatings, and each of said coatings being substantially not thicker than .1% of its radius.
2. Preparation according to claim 1 wherein said medically active impregnation contains nitroglycerin and said total amount of ethylcellulose coating material is approximately 1.5 ofthe weight of the medically inactive carrier, and wherein each of said coatings has a thickness of the order of .000025 inch; said carriers having a granule diameter of .05 inch; the diameter of the largest medically active coated carrier being approximately greater than the diameter of the smallest medically active coated carrier.
3. Preparation according to claim 1 in the form of a tablet wherein each of said medically impregnated ethylcellulose coated carriers is additionally provided with at least 25 ethylcellulose top coatings containing a total amount of coating material of the order of 1.5 of the weight of the medically inactive carrier; said amount being divided substantially equally among said 25 top coatings, and each of said top coatings being substantially not thicker than .1% of its radius.
4. In a coating process, the steps of coating medically inactive granules in a rotating pan to a substantially round shape, sieving the granules to a substantially equal size, impregnating said granules with a medicating substance in an ethylcellulose solution and coating thereon an action delaying ethylcellulose layer in the form of at least 25 substantially separate successive coating steps; the 25 coatings containing a total amount of coating material of the order of 1% of the weight of the medically inactive granule substantially equally divided among said 25 coatings; each coating being followed by an intermediate drying step and each action delaying coating having a thickness of the order of 1/10% of the radius of the medically inactive granule.
5. Process according to claim 4 wherein said medically active impregnation contains nitroglycerin and said total amount of ethylcellulose coating material is approximate- Lio ly 1.5 of the weight of the medically inactive granule and, wherein said granules are of the order of .05 inch diameter, each coating being ofthe order of .000025 inch; and wherein there are a further number of medically impregnated granules coated in said pan and provided with so many successive ethylcellulose coatings as to increase the diameter of the coated granules to approximately 30% of the diameter of the medically impregnated granules containing only 25 ethylcellulose coatings; the thickness of all the coatings on different granules being a multiple of the thickness of all the coatings on said granules containing only 25 ethylcellulose coatings.
6. Process according to claim 4 wherein said granules are coated with a highly evaporative solution of ethylceliulose and in a coating pan rotating at a speed of around 50 to 60 R. P. M., the ethylcellulose being dissolved, immediately prior to rotation, in said solution; said solution containing as a solvent at least of at least one of the group consisting of alcohol and chloroform.
7. Process according to claim 4 wherein a predetermined batch of granules is placed in the rotating pan and rotated at a speed of about 50 to 60 R. P. M. for a duration of tive minutes, the operation being repeated 25 times whereby each time substantially the same amount of ethylcellulose is applied in a solution containing fractions of beeswax and castor oil and as a solvent at least 85% of at least one of the group consisting of alcohol and chloroform, each time followed by a fifteen minute drying period, and wherein thereafter a predetermined fraction of said batch is removed from said pan and a coating solution is applied to the remaining batch in an amount substantially in the same proportion to the remaining batch as applied previously to the entire batch, and the pan is again rotated in twenty-live separate operations each lasting tive minutes; followed by fifteen minute drying periods; whereupon again a fraction of granules substantially equal to the fraction previously removed is removed from the pan, and the granules remaining in the pan are coated in the previous manner, said removing and coating operations being repeated until a desired number of batches of granules is obtained; the coatings of each batch representing multiples of twenty-tive coatings, there being interposed after each coating step a powder dusting step consisting of the application of talcum of about 1,000 to 10,000 mesh vand of an amount substantially not higher than that of the ethylcellulose in one finished coating; whereupon predetermined amounts of granules of each batch are formed into a predetermined shape providing a predetermined amount of action delay.
8. Process according to claim 4 in the manufacture of a tablet wherein each of said medically impregnated ethylcellulose granules `is additionally provided with at least 25 ethylcellulose top coatings containing a total amount of coating material of the order of 1.5% of the weight of the medically inactive granules; said amount being divided substantially equally among said 25 top coatings, and each of said top coatings being substantially not thicker than .1% of its radius.
References Cited in the lile of this patent UNITED STATES PATENTS 2,196,768 Hiatt Apr. 9, 1940 2,540,979 Clymer et al. Feb. 6, 1951 2,714,084 Hermelin July 26, 1955 2,736,682 Hermelin Feb. 28, 1956 2,738,303 Blythe Mar. 13, 1956 FOREIGN PATENTS 109,438 Australia Jan. 1l, 1940 OTHER REFERENCES Celet: Drug and Cos. Ind., September 1948, vol. 63, No. 3, p. 286.
Clarkson: Tablet Coating, 1951, Drug and Cos. Ind., N. Y., pp. 59-.65.

Claims (1)

1. IN A MEDICALLY ACTIVE SHAPED PREPARATION, A NUMBER OF SUBSTANTIALLY ROUND MEDICALLY INACTIVE GRANULATED CARRIERS, EACH HAVING AN IMPREGNATION OF A SOLUTION OF THERAPEUTICALLY ACTIVE MATERIAL IN ETHYLCELLULOSE AND UPON SAID IMPREGNATION A NUMBER OF ACTION-DELAYING ETHYLCELLULOSE COATINGS, THE NUMBER OF CAOTINGS ON AT LEAST SOME OF SAID CARRIRS BEING DIFFERENT FROM THE NUMBER ON THE REMAINING CARRIERS BY AT LEAST 25; AND 25 COATING CONTAINING A TOTAL AMOUNT OF COATING MATERIAL OF THE ORDER OF 1% OF THE WEIGHT OF THE INACTIVE CARRIER SUBSTANTIALLY EQUALLY DIVIDED AMONG SAID 25 COATINGS, AND EACH OF SAID COATINGS BEING SUBSTANTIALLY NOT THICKER THAN 1% OF ITS RADIUS.
US598841A 1956-01-25 1956-07-19 Ethyl cellulose coatings for shaped medicinal preparations Expired - Lifetime US2853420A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US598841A US2853420A (en) 1956-01-25 1956-07-19 Ethyl cellulose coatings for shaped medicinal preparations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US857550XA 1956-01-25 1956-01-25
US598841A US2853420A (en) 1956-01-25 1956-07-19 Ethyl cellulose coatings for shaped medicinal preparations

Publications (1)

Publication Number Publication Date
US2853420A true US2853420A (en) 1958-09-23

Family

ID=26773049

Family Applications (1)

Application Number Title Priority Date Filing Date
US598841A Expired - Lifetime US2853420A (en) 1956-01-25 1956-07-19 Ethyl cellulose coatings for shaped medicinal preparations

Country Status (1)

Country Link
US (1) US2853420A (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3080294A (en) * 1960-10-20 1963-03-05 Key Pharma Sustained release type of pharmaceutical vehicles
US3109775A (en) * 1961-01-31 1963-11-05 Key Pharma Theophylline-noscapine sustained release composition for treatment of asthma
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3138544A (en) * 1961-05-03 1964-06-23 British Drug Houses Canada Ltd Microbial sensitivity testing device
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
US3157484A (en) * 1961-09-14 1964-11-17 Joseph Seiberlich Tree killing agents
US3159544A (en) * 1963-02-11 1964-12-01 Smith Kline French Lab Method of printing pharmaceutical forms and product thereof
US3166476A (en) * 1961-09-01 1965-01-19 Lowey Hans Powder based tablets
US3223513A (en) * 1959-10-14 1965-12-14 Plant Products Corp Pesticidal resin and method of preparing same
US3328256A (en) * 1963-05-27 1967-06-27 William E Gaunt Spherical beads and their production
US3344029A (en) * 1963-06-03 1967-09-26 U S Ethicals Inc Sustained release composition
US3362880A (en) * 1963-09-20 1968-01-09 Dow Chemical Co Compressed drug tablets of ethyl cellulose, glyceryl monostearate, karaya gum, tragacanth, talc, and magnesium stearate
US3380998A (en) * 1963-06-03 1968-04-30 Takeda Chemical Industries Ltd Cellulose derivatives and their application for coating agents
US3383283A (en) * 1964-01-24 1968-05-14 Merck & Co Inc Medicinal pellets coated with overlapping porous fatty acid leaflet layers
US3437728A (en) * 1964-06-15 1969-04-08 Diwag Chemische Fabriken Gmbh Protracted release pharmaceutical compositions
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3835221A (en) * 1970-03-05 1974-09-10 Hoechst Ag Orally administrable drug dosage form having delayed action
US3924737A (en) * 1973-04-09 1975-12-09 Ciba Geigy Corp Storage-stable multi-component thermosetting resin system
DE2740286A1 (en) * 1977-06-01 1978-12-07 Ici Ltd PHARMACEUTICAL COMPOSITION WITH DELAYED DELIVERY OF ACTIVE SUBSTANCE
US4261971A (en) * 1978-12-05 1981-04-14 Aktiebolaget Hassle Pharmaceutically preparation comprising a cardiac glycoside in combination with a polymer
US4263273A (en) * 1978-12-22 1981-04-21 Aktiebolaget Astra Pharmaceutical preparation comprising a cardiac glycoside with a polymer coating
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4361546A (en) * 1978-07-15 1982-11-30 Boehringer Ingelheim Gmbh Retard form of pharmaceuticals with insoluble porous diffusion coatings
US4367217A (en) * 1980-01-12 1983-01-04 Boehringer Ingelheim Gmbh Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
WO1983000284A1 (en) * 1981-07-15 1983-02-03 Key Pharma Sustained release theophylline
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
WO1984000004A1 (en) * 1982-06-14 1984-01-05 Key Pharma Sustained release aspirin
WO1984000295A1 (en) * 1982-07-09 1984-02-02 Key Pharma Sustained release quinidine dosage form
US4432966A (en) * 1979-12-10 1984-02-21 Roussel-Uclaf Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4609542A (en) * 1978-12-22 1986-09-02 Elan Corporation, P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4632843A (en) * 1983-02-23 1986-12-30 Basf Aktiengesellschaft Process for the preparation of solid pharmaceutical products
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4748023A (en) * 1983-01-26 1988-05-31 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
US4800084A (en) * 1984-02-01 1989-01-24 Horst Zerbe Pharmaceutical product in the form of a pellet with continuous, delayed medicament substance emission
US4820521A (en) * 1983-04-06 1989-04-11 Eland Corporation P.L.C. Sustained absorption pharmaceutical composition
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
DE4100920A1 (en) * 1991-01-15 1992-07-16 Degussa ACTIVE SUBSTANCE PREPARATION FOR ORAL ADMINISTRATION TO Ruminants
US5219621A (en) * 1987-10-16 1993-06-15 Elan Corporation, Plc Methods of treatment with diltiazem formulations
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US20040067306A1 (en) * 2000-11-16 2004-04-08 Jean-Pierre Mathonnet Method for making granules
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2196768A (en) * 1938-03-11 1940-04-09 Eastman Kodak Co Enteric coating
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
US2714084A (en) * 1954-10-11 1955-07-26 Victor M Hermelin Enteric coated tablets and methods of making the same
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2196768A (en) * 1938-03-11 1940-04-09 Eastman Kodak Co Enteric coating
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2714084A (en) * 1954-10-11 1955-07-26 Victor M Hermelin Enteric coated tablets and methods of making the same
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3223513A (en) * 1959-10-14 1965-12-14 Plant Products Corp Pesticidal resin and method of preparing same
US3080294A (en) * 1960-10-20 1963-03-05 Key Pharma Sustained release type of pharmaceutical vehicles
US3109775A (en) * 1961-01-31 1963-11-05 Key Pharma Theophylline-noscapine sustained release composition for treatment of asthma
US3138544A (en) * 1961-05-03 1964-06-23 British Drug Houses Canada Ltd Microbial sensitivity testing device
US3166476A (en) * 1961-09-01 1965-01-19 Lowey Hans Powder based tablets
US3157484A (en) * 1961-09-14 1964-11-17 Joseph Seiberlich Tree killing agents
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
US3159544A (en) * 1963-02-11 1964-12-01 Smith Kline French Lab Method of printing pharmaceutical forms and product thereof
US3328256A (en) * 1963-05-27 1967-06-27 William E Gaunt Spherical beads and their production
US3380998A (en) * 1963-06-03 1968-04-30 Takeda Chemical Industries Ltd Cellulose derivatives and their application for coating agents
US3344029A (en) * 1963-06-03 1967-09-26 U S Ethicals Inc Sustained release composition
US3362880A (en) * 1963-09-20 1968-01-09 Dow Chemical Co Compressed drug tablets of ethyl cellulose, glyceryl monostearate, karaya gum, tragacanth, talc, and magnesium stearate
US3383283A (en) * 1964-01-24 1968-05-14 Merck & Co Inc Medicinal pellets coated with overlapping porous fatty acid leaflet layers
US3437728A (en) * 1964-06-15 1969-04-08 Diwag Chemische Fabriken Gmbh Protracted release pharmaceutical compositions
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3835221A (en) * 1970-03-05 1974-09-10 Hoechst Ag Orally administrable drug dosage form having delayed action
US3924737A (en) * 1973-04-09 1975-12-09 Ciba Geigy Corp Storage-stable multi-component thermosetting resin system
US4138475A (en) * 1977-06-01 1979-02-06 Imperial Chemical Industries Limited Sustained release pharmaceutical composition
DE2740286A1 (en) * 1977-06-01 1978-12-07 Ici Ltd PHARMACEUTICAL COMPOSITION WITH DELAYED DELIVERY OF ACTIVE SUBSTANCE
US4361546A (en) * 1978-07-15 1982-11-30 Boehringer Ingelheim Gmbh Retard form of pharmaceuticals with insoluble porous diffusion coatings
US4459279A (en) * 1978-07-15 1984-07-10 Boehringer Ingelheim Gmbh Retard form of pharmaceuticals with insoluble porous diffusion coatings
US4261971A (en) * 1978-12-05 1981-04-14 Aktiebolaget Hassle Pharmaceutically preparation comprising a cardiac glycoside in combination with a polymer
US4263273A (en) * 1978-12-22 1981-04-21 Aktiebolaget Astra Pharmaceutical preparation comprising a cardiac glycoside with a polymer coating
US4726951A (en) * 1978-12-22 1988-02-23 Elan Corporation P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4609542A (en) * 1978-12-22 1986-09-02 Elan Corporation, P.L.C. New pharmaceutical forms for administration of medicaments by oral route, with programmed release
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4432966A (en) * 1979-12-10 1984-02-21 Roussel-Uclaf Compressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
US4367217A (en) * 1980-01-12 1983-01-04 Boehringer Ingelheim Gmbh Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
WO1983000284A1 (en) * 1981-07-15 1983-02-03 Key Pharma Sustained release theophylline
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
WO1984000004A1 (en) * 1982-06-14 1984-01-05 Key Pharma Sustained release aspirin
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
WO1984000295A1 (en) * 1982-07-09 1984-02-02 Key Pharma Sustained release quinidine dosage form
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4748023A (en) * 1983-01-26 1988-05-31 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
US4632843A (en) * 1983-02-23 1986-12-30 Basf Aktiengesellschaft Process for the preparation of solid pharmaceutical products
US4820521A (en) * 1983-04-06 1989-04-11 Eland Corporation P.L.C. Sustained absorption pharmaceutical composition
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
US5616345A (en) * 1983-12-22 1997-04-01 Elan Corporation Plc Controlled absorption diltiazen formulation for once-daily administration
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4800084A (en) * 1984-02-01 1989-01-24 Horst Zerbe Pharmaceutical product in the form of a pellet with continuous, delayed medicament substance emission
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US5219621A (en) * 1987-10-16 1993-06-15 Elan Corporation, Plc Methods of treatment with diltiazem formulations
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
DE4100920A1 (en) * 1991-01-15 1992-07-16 Degussa ACTIVE SUBSTANCE PREPARATION FOR ORAL ADMINISTRATION TO Ruminants
US5279832A (en) * 1991-01-15 1994-01-18 Degussa Ag Active-substance preparation for oral administration, especially to ruminants
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US20100034876A1 (en) * 1993-06-18 2010-02-11 Purdue Pharma L.P. Controlled release oxycodone compositions
US20040067306A1 (en) * 2000-11-16 2004-04-08 Jean-Pierre Mathonnet Method for making granules
US7674496B2 (en) * 2000-11-16 2010-03-09 Laboratoires Docteur Gaetano Zannini Method for making granules

Similar Documents

Publication Publication Date Title
US2853420A (en) Ethyl cellulose coatings for shaped medicinal preparations
US3080294A (en) Sustained release type of pharmaceutical vehicles
US3492397A (en) Sustained release dosage in the pellet form and process thereof
US4438091A (en) Bromhexine delayed-release pharmaceutical form
US2991226A (en) Long-acting wax-like talc pillage of penicillin
CA1332567C (en) Sustained release pharmaceutical composition
US4427648A (en) Dipyridamole-containing pharmaceutical form
US3119742A (en) Method of preparing sustained release pharmaceutical pellets and product thereof
US5246714A (en) Drug preparation
EP0122077A2 (en) Sustained absorption pharmaceutical composition
US5397574A (en) Controlled release potassium dosage form
GB1326995A (en) Orally administrable drug dosage form having delayed action
US3365365A (en) Repeat action pharmaceutical compositions in the form of discrete beadlets
NZ232030A (en) Sustained release pharmaceutical pellet composition; theophylline compound core, coated to allow faster release rate in intestine
JP2011026337A (en) Film coating for tablet and caplet
CH678813A5 (en)
US4025613A (en) Timed-release aspirin
RU2239435C2 (en) Stavudine-containing sustained-release granule
KR890007743A (en) Slow Release Galenical Compositions of Pharmaceutically Acceptable Diltiazem
JPH02106A (en) Chewable drug tablet containing taste sensation blocking agent
US2536168A (en) Amphetamine chewing gum
JPS6133113A (en) Manufacture of release-delay microgranule etofibrate or analogue compound
US3166476A (en) Powder based tablets
EP1109535A1 (en) Extended release acetaminophen
US2963402A (en) Sustained release medicament